-
US threatens 'devastating' response to any Iran attack on shipping
-
Murphy warns snooker hopefuls to 'work harder' to match Chinese stars
-
Race to find port for hantavirus-stricken cruise ship
-
Romanian pro-EU PM loses no-confidence motion
-
Stocks diverge as traders eye US-Iran ceasefire
-
Edin Terzic to become Athletic Bilbao coach next season
-
Borthwick backed by RFU to take England to 2027 Rugby World Cup
-
EU hails 'leap forward' in ties with Russia's ally Armenia
-
German car-ramming suspect had mental health problems: reports
-
Pyongyang calling: North Korea shows off own-brand phones
-
Iran warns 'not even started' in Hormuz
-
World body in dark over allegations against China badminton chief
-
Asian stocks drop amid fears over US-Iran ceasefire
-
China fireworks factory explosion kills 26, injures 61
-
China hails 'our era' as Wu Yize's world snooker triumph goes viral
-
Ex-model accuses French scout of grooming her for Epstein
-
Timberwolves eclipse Spurs as Knicks rout Sixers
-
Taiwan leader says island has 'right to engage with the world'
-
Yoko says oh no to 'John Lemon' beer
-
Bayern's Kompany promises repeat fireworks in PSG Champions League semi
-
A coaching great? Luis Enrique has PSG on brink of another Champions League final
-
Top five moments from the Met Gala
-
Brunson leads Knicks in rout of Sixers
-
Retiring great Sophie Devine wants New Zealand back playing Tests
-
Stocks sink amid fears over US-Iran ceasefire
-
G7 trade ministers set to meet but not discuss latest US tariff threat
-
Sherlock Holmes fans recreate fateful duel at Swiss falls
-
Premier League losses soar for clubs locked in 'arms race'
-
'Spreading like wildfire': Fiji grapples with soaring HIV cases
-
For Israel's Circassians, food and language sustain an ancient heritage
-
'Super El Nino' raises fears for Asia reeling from Middle East conflict
-
Trouble in paradise: Colombia tourist jewel plagued by violence
-
Death toll in Brazil small plane crash rises to three
-
Pulitzers honor damning coverage of Trump and his policies
-
Digi Power X Signs AI Colocation Agreement with Leading AI Compute Company for 40 MW Data Center in Columbiana, Alabama
-
LA fire suspect had grudge against wealthy: prosecutors
-
US-Iran ceasefire on brink as UAE reports attacks
-
Stars shine at Met Gala, fashion's biggest night
-
Birthday girl, 10, among dead in Colombia monster truck crash
-
Blake Lively, Justin Baldoni agree to end lengthy legal battle
-
Dolly Parton cancels Las Vegas shows over health concerns
-
Wu Yize: China's 'priest' who conquered the snooker world
-
China's Wu Yize wins World Snooker Championship for first time
-
Broadway theater blaze forces 'Book of Mormon' to close
-
Advantage Arsenal as Man City held in six-goal Everton thriller
-
Roma hammer Fiorentina to remain in Champions League hunt
-
MLB Tigers star pitcher Skubal to undergo elbow surgery
-
Oil prices jump on Hormuz tensions as US indices retreat from records
-
No.6 Morikawa withdraws from final PGA Championship tuneup
-
Ukraine and Russia declare separate truces
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
E.Schubert--BTB